Liposomal muramyl tripeptide (CGP 19835a lipid) therapy for resectable melanoma in patients who were at high risk for relapse: An update

Cancer Biotherapy and Radiopharmaceuticals

Volumn 13, Issue 5, 1998, Pages 363-365

  Gianan, Mary Ann V ^a   Kleinerman, Eugenie S ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

L MTP PE; Long term disease free survival; Macrophage activation; Melanoma

Indexed keywords

N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; ERADICATION THERAPY; FEMALE; HIGH RISK POPULATION; HUMAN; MACROPHAGE ACTIVATION; MALE; MELANOMA; METASTASIS; NEEDLE BIOPSY; PILOT STUDY; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 0032408130     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1998.13.363     Document Type: Article

References (19)

1. Landis S, Murray T, Bolden S, Wingo P. Cancer Statistics 1998. CA-A Cancer Journal for Clinicians 1998;48(1):6-29.
2. Reintgen D, Ross M, Bland K, Seigler HF, Balch C. Prevention and early detection of melanoma: A surgeon's perspective. Seminars in Surgical Oncology 1993; 9(3):174-187.
3. Balch C, Soong S, Shaw H, Urist M, McCarthy W. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. Cutaneous Melanoma 1992;14:165-187.
4. Friedman R, Rigel D, Silverman M, Kopf A, Vossaert K. Malignant Melanoma in the 1990's: The continued importance of early detection and the role of physician examination and self-examination of the skin. CA-A Cancer Journal for Clinicians 1991;41(4):201-226.
5. Legha S, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple drug regimen containing cisplatin, vinblastine and dacarbazine (CVD) for metastatic melanoma. Cancer 1989;64:2024-2029.
6. Schroit AJ, Fiddler IJ. Effects of liposome structure and lipid composition on the activation of tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 1982;43:161-167.
7. Fidler IJ, Kleinerman ES. Lymphokine activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. Clin Oncol 1984;2:937-943.
8. Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ. Activation of tumoricidal properties in human blood monocytes by liposomes containing muramyl tripeptide. Cancer Res 1983;43:2010-2014.
9. Fidler IJ, Barnes Z, Fogler WE, Kirsch R, Bugelski P, Poste F. Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res 1982;40:496-501.
10. Poste F, Bucana Z, Raz A, Bugelski P, Kirsch R, Fiddler IJ. Analysis of the fate of systematically administered liposomes and implications for their use in drug delivery. Cancer Res 1982;42: 1412-1422.
11. Fidler IJ, Sone S, Fogler WE, Barnes Z. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide (abstract). In: Clark RL, Cumley RN, Hickey RC (eds.): Year Book of Cancer 1982, pp. 384-387.
12. McEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howar PE. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. Journal of National Cancer Institute 1989;81:935-938.
13. Murray JL, Kleinerman ES, Cunningham JE, Tatom JR, Andrejcio K, Lepe-Zuniga J, Lamki LM, Rosenblum MG, Frost H, Gutterman JU, Fidler IJ, Krakoff IH. Phase I trial of liposomal muramyl tripeptide phosphatidyl ethanolamine in cancer patients. Clin Oncol 1989;7:1915-1925.
14. Creaven PJ, Cowens JW, Brenner DE, Dadey BM, Han T, Huben R, Karakousis C, Frost H, LeSher D, Hanagan J, Andrejcio K, Cushman MK. Initial clinical trial of the macrophage activation muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes in patients with advanced cancer. Journal of Biological Response Modifiers 1990;9:492-498.
15. Kleinerman ES, Murray JL, Snyder JS, Cunningham JE, Fidler IJ. Activation of tumoricidal properties in monocytes from cancer patients following intravenous administration of liposomes containing muramyl tripeptide phosphatidyl ethanolamine. Cancer Res 1989;49:4665-4670.
16. Kleinerman ES, Gano JB, Johnston DA, Benjamin RS Jaffe N. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am Clin Oncol 1995;18:93-99.
17. Kleinerman ES, Raymond AK, Bucana CD, Jaffe N, Harris MB, Krakorff IH, Benjamin R, Fidler IJ. Unique histolological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835 A Lipid). Cancer Immunology and Immnnotherapy 1992;34:211-220.
18. Fidler I, Post G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Seminars in Immunopathology 1982;5:161-174.
19. Fujimaki W, Itoh K, An T, Gano J, Ross M, Mansfield P, Balch C, Augustus L, Karkevitch D, Johnston D, Fidler IJ, Kleinerman E. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A Lipid). Cancer Biotherapy 1993;8(4):307-317